Herpes zoster virus of shingles
About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read morePress releases
- IAS 2019: ViiV Healthcare showcasing innovation in HIV science
- GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
- ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Tweets from GSK
-
GSK @GSK
ViiV Healthcare are heading to Mexico for #IAS2019 where they’ll be discussing all the latest in #HIV/#AIDS research. Follow @ViiVHC for live updates! twitter.com/ViiVHC/status/…
about 16 hours ago
-
GSK @GSK
We’re proud to be named a @stonewalluk #StonewallTopGlobal employer for #LGBTinclusion. This is a fantastic achievement for all our colleagues around the world. Read the full report: gsk.to/2Y6487Q twitter.com/stonewalluk/st…
about 23 hours ago
-
GSK @GSK
Science is at the heart of everything we do. Come #BehindTheScience with us every Friday as we share our favourite stories from inside and outside our labs.
about 3 days ago
